Unraveling the Chemotherapeutic Potential of Taxifolin Ruthenium-p-cymene Complex in Breast Carcinoma: Insights into AhR Signaling Pathway in Vitro and in Vivo

Overview

Journal Transl Oncol

Specialty Oncology

Date 2024 Aug 24

PMID 39181115

Authors

Abhijit Das

Barshana Bhattacharya

Sakuntala Gayen

Souvik Roy

Affiliations

Soon will be listed here.

Abstract

Background: Mammary carcinoma is the most frequently diagnosed form of carcinoma in women worldwide. The organometallic compounds showed a prospective anticancer activity. This research explored the anticancer efficacy of taxifolin ruthenium-p-cymene counter to breast cancer.

Methods: The anticancer efficacy of the novel organometallic compound was investigated via various in vitro and in vivo techniques using breast cancer cell lines and breast cancer model of rat.

Results: Target proteins were identified via pharmacophore analysis, which revealed a high binding affinity towards AhR, EGFR, and β-catenin. The compound induced apoptotic events and prevented cancer cell colony formation. Furthermore, decreased expression of AhR, EGFR, and N-cadherin inhibited cancer cell growth, migration, and proliferation. The compound provoked the cell cycle arrest at sub G0/G1 phase, S phase and G2/M phase and inaugurated the caspase-3 dependent apoptotic events. The in-vivo experimentation displayed the fruitful restoration of breast tissue since the complex treatment in DMBA persuaded breast carcinoma in rat. Moreover, the upstream of p53 and caspase-3 expression along with substantially downstream of vimentin, β-catenin, m-TOR and Akt expression.

Conclusions: In conclusion, the compound repressed the cancerous cellular viability, migration, and EMT via modulating the AhR/EGFR/ PI3K transduction pathway and the expression of EMT biomarkers such as N-cadherin, E-cadherin, thus eventually revoked the EMT facilitated metastasis of malignant cells.

References

Jin Z, El-Deiry W . Overview of cell death signaling pathways. Cancer Biol Ther. 2005; 4(2):139-63. DOI: 10.4161/cbt.4.2.1508. View

Rivlin N, Brosh R, Oren M, Rotter V . Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of Tumorigenesis. Genes Cancer. 2011; 2(4):466-74. PMC: 3135636. DOI: 10.1177/1947601911408889. View

Masuda H, Zhang D, Bartholomeusz C, Doihara H, Hortobagyi G, Ueno N . Role of epidermal growth factor receptor in breast cancer. Breast Cancer Res Treat. 2012; 136(2):331-45. PMC: 3832208. DOI: 10.1007/s10549-012-2289-9. View

Das A, Baidya R, Chakraborty T, Samanta A, Roy S . Pharmacological basis and new insights of taxifolin: A comprehensive review. Biomed Pharmacother. 2021; 142:112004. DOI: 10.1016/j.biopha.2021.112004. View

Huang Y, He J, Liang H, Hu K, Jiang S, Yang L . Aryl Hydrocarbon Receptor Regulates Apoptosis and Inflammation in a Murine Model of Experimental Autoimmune Uveitis. Front Immunol. 2018; 9:1713. PMC: 6068235. DOI: 10.3389/fimmu.2018.01713. View

Khan F, Owusu-Tieku N, Dai X, Liu K, Wu Y, Tsai H . Wnt/β-Catenin Pathway-Regulated Fibromodulin Expression Is Crucial for Breast Cancer Metastasis and Inhibited by Aspirin. Front Pharmacol. 2019; 10:1308. PMC: 6886402. DOI: 10.3389/fphar.2019.01308. View

Bekki K, Vogel H, Li W, Ito T, Sweeney C, Haarmann-Stemmann T . The aryl hydrocarbon receptor (AhR) mediates resistance to apoptosis induced in breast cancer cells. Pestic Biochem Physiol. 2015; 120:5-13. PMC: 4438266. DOI: 10.1016/j.pestbp.2014.12.021. View

Hassan M, Watari H, AbuAlmaaty A, Ohba Y, Sakuragi N . Apoptosis and molecular targeting therapy in cancer. Biomed Res Int. 2014; 2014:150845. PMC: 4075070. DOI: 10.1155/2014/150845. View

Baisch H . Elevated Ki-67 expression is correlated with TNFalpha- and IFNgamma-induced apoptosis in tumour cells. Cell Prolif. 2002; 35(6):333-42. PMC: 6495924. DOI: 10.1046/j.1365-2184.2002.00243.x. View

10.

Gramatzki D, Pantazis G, Schittenhelm J, Tabatabai G, Kohle C, Wick W . Aryl hydrocarbon receptor inhibition downregulates the TGF-beta/Smad pathway in human glioblastoma cells. Oncogene. 2009; 28(28):2593-605. DOI: 10.1038/onc.2009.104. View

11.

Sadot E, Geiger B, Oren M, Ben-Zeev A . Down-regulation of beta-catenin by activated p53. Mol Cell Biol. 2001; 21(20):6768-81. PMC: 99855. DOI: 10.1128/MCB.21.20.6768-6781.2001. View

12.

Rodriguez M, Potter D . CYP1A1 regulates breast cancer proliferation and survival. Mol Cancer Res. 2013; 11(7):780-92. PMC: 3720830. DOI: 10.1158/1541-7786.MCR-12-0675. View

13.

Faust D, Vondracek J, Krcmar P, Smerdova L, Prochazkova J, Hruba E . AhR-mediated changes in global gene expression in rat liver progenitor cells. Arch Toxicol. 2012; 87(4):681-98. DOI: 10.1007/s00204-012-0979-z. View

14.

Feng S, Cao Z, Wang X . Role of aryl hydrocarbon receptor in cancer. Biochim Biophys Acta. 2013; 1836(2):197-210. DOI: 10.1016/j.bbcan.2013.05.001. View

15.

Clevers H . Wnt/beta-catenin signaling in development and disease. Cell. 2006; 127(3):469-80. DOI: 10.1016/j.cell.2006.10.018. View

16.

Miricescu D, Totan A, Stanescu-Spinu I, Badoiu S, Stefani C, Greabu M . PI3K/AKT/mTOR Signaling Pathway in Breast Cancer: From Molecular Landscape to Clinical Aspects. Int J Mol Sci. 2020; 22(1). PMC: 7796017. DOI: 10.3390/ijms22010173. View

17.

Shiizaki K, Kido K, Mizuta Y . Insight into the relationship between aryl-hydrocarbon receptor and β-catenin in human colon cancer cells. PLoS One. 2019; 14(11):e0224613. PMC: 6824560. DOI: 10.1371/journal.pone.0224613. View

18.

Zhuo Z, Hu J, Yang X, Chen M, Lei X, Deng L . Ailanthone Inhibits Huh7 Cancer Cell Growth via Cell Cycle Arrest and Apoptosis In Vitro and In Vivo. Sci Rep. 2015; 5:16185. PMC: 4630794. DOI: 10.1038/srep16185. View

19.

Vacher S, Castagnet P, Chemlali W, Lallemand F, Meseure D, Pocard M . High AHR expression in breast tumors correlates with expression of genes from several signaling pathways namely inflammation and endogenous tryptophan metabolism. PLoS One. 2018; 13(1):e0190619. PMC: 5761880. DOI: 10.1371/journal.pone.0190619. View

20.

Hu T, Li C . Convergence between Wnt-β-catenin and EGFR signaling in cancer. Mol Cancer. 2010; 9:236. PMC: 2944186. DOI: 10.1186/1476-4598-9-236. View